Monte Rosa Therapeutics Ownership 2024 | Who Owns Monte Rosa Therapeutics Now?


OverviewRevenueFinancialsChart

Institutional Ownership

77.62%

Insider Ownership

0.71%

Retail Ownership

21.67%

Institutional Holders

71.00

Monte Rosa Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
NEA MANAGEMENT COMPANY, LLC14.97%3.37%7,692,298--54,230,701Mar 31, 2024
FMR LLC10.39%0.00%5,340,802-196,437-3.55%37,652,654Mar 31, 2024
PRICE T ROWE ASSOCIATES INC /MD/9.92%0.00%5,096,787155,8803.15%35,933,000Mar 31, 2024
BAKER BROS. ADVISORS LP9.56%0.43%4,916,095--34,658,470Mar 31, 2024
AVORO CAPITAL ADVISORS LLC8.82%0.37%4,535,000--31,971,750Mar 31, 2024
BLACKROCK INC.4.49%0.00%2,307,009-64,971-2.74%16,264,413Mar 31, 2024
VANGUARD GROUP INC3.18%0.00%1,635,82947,4122.98%11,532,595Mar 31, 2024
AISLING CAPITAL MANAGEMENT LP2.86%3.51%1,472,331--10,379,934Mar 31, 2024
ALPHABET INC.2.85%0.41%1,464,015--10,321,305Mar 31, 2024
CITADEL ADVISORS LLC1.91%0.00%980,239-3,546-0.36%6,910,685Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC1.43%0.00%735,53347,8626.96%5,186,095Mar 31, 2024
STATE STREET CORP1.20%0.00%615,25141,8427.30%4,337,520Mar 31, 2024
CASDIN CAPITAL, LLC0.99%0.27%510,882--3,601,718Mar 31, 2024
NORTHERN TRUST CORP0.57%0.00%290,4545,5201.94%2,047,701Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP0.52%0.01%265,27835,47415.44%1,870,000Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC0.49%0.00%250,5825,0202.04%1,766,603Mar 31, 2024
TD ASSET MANAGEMENT INC0.38%0.00%193,168--1,361,834Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.29%0.00%150,02582,746122.99%1,057,676Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.24%0.00%122,10016,90016.06%861,000Mar 31, 2024
WELLINGTON MANAGEMENT GROUP LLP0.23%0.00%120,647120,647100.00%850,561Mar 31, 2024

Monte Rosa Therapeutics's largest institutional shareholder is NEA MANAGEMENT COMPANY, LLC, holding 14.97% of the company's total share outstanding, currently valued at $54.23M. The top 10 institutional shareholders own together 68.95% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
AISLING CAPITAL MANAGEMENT LP2.86%3.51%1,472,331--10,379,934Mar 31, 2024
NEA MANAGEMENT COMPANY, LLC14.97%3.37%7,692,298--54,230,701Mar 31, 2024
BAKER BROS. ADVISORS LP9.56%0.43%4,916,095--34,658,470Mar 31, 2024
ALPHABET INC.2.85%0.41%1,464,015--10,321,305Mar 31, 2024
AVORO CAPITAL ADVISORS LLC8.82%0.37%4,535,000--31,971,750Mar 31, 2024
CASDIN CAPITAL, LLC0.99%0.27%510,882--3,601,718Mar 31, 2024
LONG CORRIDOR ASSET MANAGEMENT LTD0.08%0.25%40,00040,000100.00%282,000Mar 31, 2024
ENTRYPOINT CAPITAL, LLC0.03%0.10%15,89315,893100.00%112,046Mar 31, 2024
CORNERCAP INVESTMENT COUNSEL INC0.08%0.05%42,39314,54952.25%298,871Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP0.52%0.01%265,27835,47415.44%1,870,000Mar 31, 2024
PDT PARTNERS, LLC0.03%0.01%13,95513,955100.00%98,383Mar 31, 2024
EXCHANGE TRADED CONCEPTS, LLC0.09%0.01%46,78723,460100.57%329,848Mar 31, 2024
SARASIN & PARTNERS LLP0.13%0.00%65,081--458,821Mar 31, 2024
PRICE T ROWE ASSOCIATES INC /MD/9.92%0.00%5,096,787155,8803.15%35,933,000Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%16,89816,898100.00%119,131Mar 31, 2024
FMR LLC10.39%0.00%5,340,802-196,437-3.55%37,652,654Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC0.11%0.00%55,54826,68792.47%390,000Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.24%0.00%122,10016,90016.06%861,000Mar 31, 2024
CITADEL ADVISORS LLC1.91%0.00%980,239-3,546-0.36%6,910,685Mar 31, 2024
TD ASSET MANAGEMENT INC0.38%0.00%193,168--1,361,834Mar 31, 2024

The largest Monte Rosa Therapeutics shareholder by % of total assets is AISLING CAPITAL MANAGEMENT LP. The company owns 1.47M shares of Monte Rosa Therapeutics (GLUE), representing 3.51% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PRICE T ROWE ASSOCIATES INC /MD/9.92%0.00%5,096,787155,8803.15%35,933,000Mar 31, 2024
WELLINGTON MANAGEMENT GROUP LLP0.23%0.00%120,647120,647100.00%850,561Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.29%0.00%150,02582,746122.99%1,057,676Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.13%0.00%65,00065,000100.00%458,250Mar 31, 2024
DIMENSIONAL FUND ADVISORS LP0.14%0.00%72,67548,362198.91%512,359Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC1.43%0.00%735,53347,8626.96%5,186,095Mar 31, 2024
VANGUARD GROUP INC3.18%0.00%1,635,82947,4122.98%11,532,595Mar 31, 2024
STATE STREET CORP1.20%0.00%615,25141,8427.30%4,337,520Mar 31, 2024
LONG CORRIDOR ASSET MANAGEMENT LTD0.08%0.25%40,00040,000100.00%282,000Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP0.52%0.01%265,27835,47415.44%1,870,000Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC0.11%0.00%55,54826,68792.47%390,000Mar 31, 2024
STATE OF WISCONSIN INVESTMENT BOARD0.10%0.00%52,80025,00089.93%372,240Mar 31, 2024
EXCHANGE TRADED CONCEPTS, LLC0.09%0.01%46,78723,460100.57%329,848Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.24%0.00%122,10016,90016.06%861,000Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%16,89816,898100.00%119,131Mar 31, 2024
ENTRYPOINT CAPITAL, LLC0.03%0.10%15,89315,893100.00%112,046Mar 31, 2024
CORNERCAP INVESTMENT COUNSEL INC0.08%0.05%42,39314,54952.25%298,871Mar 31, 2024
PDT PARTNERS, LLC0.03%0.01%13,95513,955100.00%98,383Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.02%-11,40011,400100.00%80,370Mar 31, 2024
AMERICAN CENTURY COMPANIES INC0.07%0.00%33,8487,56828.80%238,628Mar 31, 2024

As of Mar 31 2024, Monte Rosa Therapeutics's largest institutional buyer is PRICE T ROWE ASSOCIATES INC /MD/. The company purchased 155.88K stocks of GLUE, valued at $35.93M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CAPTION MANAGEMENT, LLC----224,300-100.00%-Mar 31, 2024
FMR LLC10.39%0.00%5,340,802-196,437-3.55%37,652,654Mar 31, 2024
CANDRIAM S.C.A.----135,000-100.00%-Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP----100,000-100.00%-Mar 31, 2024
BLACKROCK INC.4.49%0.00%2,307,009-64,971-2.74%16,264,413Mar 31, 2024
HRT FINANCIAL LP----63,204-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC0.04%-22,163-48,552-68.66%156,249Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.----48,511-100.00%-Mar 31, 2024
UBS OCONNOR LLC----44,247-100.00%-Mar 31, 2024
BARCLAYS PLC0.04%0.00%21,748-39,520-64.50%154,000Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.----38,802-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC0.03%-15,300-28,500-65.07%107,865Mar 31, 2024
MORGAN STANLEY0.11%-55,730-25,746-31.60%392,896Mar 31, 2024
GOLDMAN SACHS GROUP INC0.03%-15,764-21,414-57.60%111,136Mar 31, 2024
BANK OF AMERICA CORP /DE/0.12%-62,109-18,598-23.04%437,869,000Mar 31, 2024
SQUAREPOINT OPS LLC----17,462-100.00%-Mar 31, 2024
BELVEDERE TRADING LLC----12,900-100.00%-Mar 31, 2024
SG AMERICAS SECURITIES, LLC----12,257-100.00%-Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC----10,602-100.00%-Mar 31, 2024
INVESCO LTD.----10,518-100.00%-Mar 31, 2024

As of Mar 31 2024, Monte Rosa Therapeutics's biggest institutional seller is CAPTION MANAGEMENT, LLC. The company sold -0.22M shares of GLUE, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
WELLINGTON MANAGEMENT GROUP LLP0.23%0.00%120,647120,647100.00%850,561Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.13%0.00%65,00065,000100.00%458,250Mar 31, 2024
LONG CORRIDOR ASSET MANAGEMENT LTD0.08%0.25%40,00040,000100.00%282,000Mar 31, 2024
JUMP FINANCIAL, LLC0.03%0.00%16,89816,898100.00%119,131Mar 31, 2024
ENTRYPOINT CAPITAL, LLC0.03%0.10%15,89315,893100.00%112,046Mar 31, 2024
PDT PARTNERS, LLC0.03%0.01%13,95513,955100.00%98,383Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.02%-11,40011,400100.00%80,370Mar 31, 2024
STRS OHIO0.01%0.00%3,1003,100100.00%21,000Mar 31, 2024
GAMMA INVESTING LLC0.00%0.00%5252100.00%367Mar 31, 2024
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC--66100.00%42Mar 31, 2024

Monte Rosa Therapeutics's largest new institutional shareholder by number of shares is WELLINGTON MANAGEMENT GROUP LLP, purchased 120.65K shares, valued at $850.56K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CAPTION MANAGEMENT, LLC----224,300-100.00%-Mar 31, 2024
CANDRIAM S.C.A.----135,000-100.00%-Mar 31, 2024
EXODUSPOINT CAPITAL MANAGEMENT, LP----100,000-100.00%-Mar 31, 2024
HRT FINANCIAL LP----63,204-100.00%-Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.----48,511-100.00%-Mar 31, 2024
UBS OCONNOR LLC----44,247-100.00%-Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.----38,802-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----17,462-100.00%-Mar 31, 2024
BELVEDERE TRADING LLC----12,900-100.00%-Mar 31, 2024
SG AMERICAS SECURITIES, LLC----12,257-100.00%-Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC----10,602-100.00%-Mar 31, 2024
INVESCO LTD.----10,518-100.00%-Mar 31, 2024
SIMPLEX TRADING, LLC----10,043-100.00%-Mar 31, 2024

Monte Rosa Therapeutics's largest sold out institutional shareholder by shares sold is CAPTION MANAGEMENT, LLC, sold -0.22M shares, valued at -, as of undefined.

Monte Rosa Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
DSS AMERICAFIRST QUANTITATIVE FUNDS2.02%46,00046,000-Dec 29, 2023
T. Rowe Price Health Sciences Fund, Inc.0.19%943,654-19,613-2.04%Dec 31, 2023
CORNERCAP GROUP OF FUNDS /VA/0.19%13,61513,615-Sep 30, 2022
T. Rowe Price New Horizons Fund, Inc.0.19%2,759,581764,31538.31%Dec 31, 2023
Voya VARIABLE PRODUCTS TRUST0.12%36,189--Dec 31, 2023
PRUDENTIAL SECTOR FUNDS, INC.0.11%218,779--Feb 29, 2024
T. Rowe Price Small-Cap Stock Fund, Inc.0.11%389,927--Dec 31, 2023
BlackRock Health Sciences Trust II0.10%266,168-498,405-65.19%Dec 31, 2023
FIDELITY ADVISOR SERIES VII0.07%632,258-435,700-40.80%Jan 31, 2024
BlackRock Health Sciences Trust0.07%28,575--Dec 31, 2023
VANGUARD VALLEY FORGE FUNDS0.06%28,328--Dec 31, 2023
Vericimetry Funds0.04%4,620--Dec 31, 2023
FIDELITY MT VERNON STREET TRUST0.04%1,109,991-171,461-13.38%Feb 29, 2024
T. Rowe Price Equity Series, Inc.0.03%51,821--Dec 31, 2023
T. Rowe Price Small-Cap Value Fund, Inc.0.03%211,893--Dec 31, 2023
FIDELITY SELECT PORTFOLIOS0.03%1,736,205--Feb 29, 2024
T. Rowe Price Quantitative Management Funds, Inc.0.02%79,20014,20021.85%Dec 31, 2023
Voya EQUITY TRUST0.01%21,177--Feb 29, 2024
T. Rowe Price Equity Funds, Inc.0.01%209,491--Dec 31, 2023
FIDELITY COMMONWEALTH TRUST0.01%37,37411,00241.72%Feb 29, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.01%4,311--Dec 31, 2023
FIDELITY SECURITIES FUND0.01%852,355--Jan 31, 2024
FIDELITY CAPITAL TRUST0.01%95,973--Jan 31, 2024
QUANTITATIVE MASTER SERIES LLC0.01%55,657--Dec 31, 2023
Nushares ETF Trust0.01%53,833--Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND III0.01%54,800--Dec 31, 2023
VANGUARD INDEX FUNDS0.00%1,700,621514,10943.33%Dec 31, 2023
FIDELITY ADVISOR SERIES I0.00%419,477--Feb 29, 2024
ETF Series Solutions0.00%27,4454,39719.08%Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%308,23632,86411.93%Feb 29, 2024
T. Rowe Price Spectrum Funds II, Inc.0.00%17,265--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%29,490--Dec 31, 2023
Calvert Variable Products, Inc.0.00%2,241--Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 10.00%213--Dec 31, 2023
SCHWAB STRATEGIC TRUST0.00%166,9815,6113.48%Feb 29, 2024
T. Rowe Price Index Trust, Inc.0.00%14,462--Feb 29, 2024
Principal Exchange-Traded Funds0.00%7,996--Mar 31, 2024
VANGUARD WORLD FUND0.00%109,431-33,035-23.19%Feb 29, 2024
Voya VARIABLE PORTFOLIOS INC0.00%12,465--Dec 31, 2023
Virtus Investment Trust0.00%12,638--Dec 29, 2023
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%1,484--Dec 31, 2023
AMERICAN CENTURY ETF TRUST0.00%30,1687,04230.45%Feb 29, 2024
BlackRock ETF Trust0.00%230--Jan 31, 2024
TIAA-CREF LIFE FUNDS0.00%579--Dec 31, 2023
HC CAPITAL TRUST0.00%5,9685,6952086.08%Dec 31, 2023
THRIVENT SERIES FUND INC0.00%14,609--Dec 29, 2023
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%10,2002,00024.39%Dec 31, 2023
VARIABLE INSURANCE PRODUCTS FUND II0.00%1,481--Dec 31, 2023
EQ ADVISORS TRUST0.00%101,8781,7201.72%Dec 31, 2023
iSHARES TRUST0.00%1,189,109--Feb 29, 2024
Dimensional ETF Trust0.00%30,22626,756771.07%Jan 31, 2024
RYDEX SERIES FUNDS0.00%278--Dec 31, 2023
VANGUARD SCOTTSDALE FUNDS0.00%133,18615,58313.25%Feb 29, 2024
ProFunds0.00%43518070.59%Jan 31, 2024
VALIC Co I0.00%11,705-47-0.40%Feb 29, 2024
PENN SERIES FUNDS INC0.00%1,100--Dec 29, 2023
ALLSPRING MASTER TRUST0.00%2,453--Feb 29, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%4,852--Dec 31, 2023
GOLDMAN SACHS TRUST0.00%5,700--Feb 29, 2024
RYDEX DYNAMIC FUNDS0.00%138--Dec 31, 2023
NORTHERN FUNDS0.00%26,324-117,718-81.72%Dec 29, 2023
NATIONWIDE MUTUAL FUNDS0.00%3,737-794-17.52%Jan 31, 2024
Guggenheim Active Allocation Fund0.00%153--Feb 29, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%25,0908,02347.01%Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%40,689--Dec 31, 2023
PROSHARES TRUST0.00%4,470-2,632-37.06%Feb 29, 2024
RYDEX VARIABLE TRUST0.00%18--Dec 31, 2023
COLLEGE RETIREMENT EQUITIES FUND0.00%14,704--Dec 31, 2023
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%27,441--Dec 31, 2023
MORGAN STANLEY PATHWAY FUNDS0.00%1,250--Feb 29, 2024
Franklin Alternative Strategies Funds0.00%6,745--Feb 29, 2024
MASSMUTUAL SELECT FUNDS0.00%11,1624,14959.16%Dec 31, 2023
Brighthouse Funds Trust II0.00%21,484--Dec 31, 2023
SUNAMERICA SERIES TRUST0.00%3,455-14-0.40%Jan 31, 2024
Brinker Capital Destinations Trust0.00%536--Feb 29, 2024
T. Rowe Price Multi-Strategy Total Return Fund, Inc.0.00%1,188--Jan 31, 2024
Advisors' Inner Circle Fund III0.00%95-5-5.00%Jan 31, 2024
TRANSAMERICA SERIES TRUST0.00%5,200--Dec 31, 2023
SPDR INDEX SHARES FUNDS0.00%986--Dec 31, 2023
PACIFIC SELECT FUND0.00%12,084-23,383-65.93%Dec 31, 2023
John Hancock Funds II0.00%35,064--Feb 29, 2024
Bridge Builder Trust0.00%11,989--Dec 31, 2023
COLUMBIA FUNDS SERIES TRUST I0.00%6,154--Feb 29, 2024
BlackRock Variable Series Funds, Inc.0.00%4,328--Dec 31, 2023
SEI INSTITUTIONAL INVESTMENTS TRUST0.00%8,900--Feb 29, 2024

Monte Rosa Therapeutics's largest mutual fund holder by % of total assets is "DSS AMERICAFIRST QUANTITATIVE FUNDS", owning 46.00K shares, compromising 2.02% of its total assets.

Monte Rosa Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2471-6.58%
31 Dec, 23762.70%
30 Sep, 23747.25%
30 Jun, 2369-
31 Mar, 23691.47%
31 Dec, 2268-1.45%
30 Sep, 226923.21%
30 Jun, 22565.66%
31 Mar, 2253-
31 Dec, 2153-3.64%
30 Sep, 215514.58%
30 Jun, 2148-

As of 31 Mar 24, 71 institutions are holding Monte Rosa Therapeutics's shares, representing a decrease of -6.58% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2439,892,663-0.41%
31 Dec, 2340,056,040-4.72%
30 Sep, 2342,042,2625.78%
30 Jun, 2339,746,136-0.02%
31 Mar, 2339,755,991-3.80%
31 Dec, 2241,324,5132.71%
30 Sep, 2240,235,4733.83%
30 Jun, 2238,752,309-3.14%
31 Mar, 2240,010,49910.10%
31 Dec, 2136,340,0584.15%
30 Sep, 2134,892,1238.71%
30 Jun, 2132,095,195-

Monte Rosa Therapeutics (GLUE) has 39.89M shares outstanding as of 31 Mar 24, down -0.41% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2477.62%1.20%
31 Dec, 2380.41%1.11%
30 Sep, 2385.05%1.31%
30 Jun, 2380.54%1.24%
31 Mar, 2380.56%1.05%
31 Dec, 2287.50%1.18%
30 Sep, 2286.10%1.25%
30 Jun, 2283.04%1.13%
31 Mar, 2285.87%1.38%
31 Dec, 2179.02%1.37%
30 Sep, 2175.87%1.56%
30 Jun, 2169.79%-

As of 31 Mar 24, Monte Rosa Therapeutics is held by 77.62% institutional shareholders, representing a 1.20% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 243011.11%
31 Dec, 2327-30.77%
30 Sep, 2339-7.14%
30 Jun, 234235.48%
31 Mar, 2331-
31 Dec, 2231-16.22%
30 Sep, 223723.33%
30 Jun, 2230-16.67%
31 Mar, 22369.09%
31 Dec, 2133-
30 Sep, 2133-31.25%
30 Jun, 2148-

30 institutional shareholders have increased their position in GLUE stock as of 31 Mar 24 compared to 27 in the previous quarter (a 11.11% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 2422-15.38%
31 Dec, 232652.94%
30 Sep, 231770.00%
30 Jun, 2310-50.00%
31 Mar, 232011.11%
31 Dec, 221828.57%
30 Sep, 2214-6.67%
30 Jun, 2215114.29%
31 Mar, 227-30.00%
31 Dec, 2110-23.08%
30 Sep, 2113-
30 Jun, 21--

22 institutional shareholders have reduced their position in GLUE stock as of 31 Mar 24 compared to 26 in the previous quarter (a -15.38% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2471-6.58%39,892,663-0.41%77.62%1.20%3011.11%22-15.38%
31 Dec, 23762.70%40,056,040-4.72%80.41%1.11%27-30.77%2652.94%
30 Sep, 23747.25%42,042,2625.78%85.05%1.31%39-7.14%1770.00%
30 Jun, 2369-39,746,136-0.02%80.54%1.24%4235.48%10-50.00%
31 Mar, 23691.47%39,755,991-3.80%80.56%1.05%31-2011.11%
31 Dec, 2268-1.45%41,324,5132.71%87.50%1.18%31-16.22%1828.57%
30 Sep, 226923.21%40,235,4733.83%86.10%1.25%3723.33%14-6.67%
30 Jun, 22565.66%38,752,309-3.14%83.04%1.13%30-16.67%15114.29%
31 Mar, 2253-40,010,49910.10%85.87%1.38%369.09%7-30.00%
31 Dec, 2153-3.64%36,340,0584.15%79.02%1.37%33-10-23.08%
30 Sep, 215514.58%34,892,1238.71%75.87%1.56%33-31.25%13-
30 Jun, 2148-32,095,195-69.79%-48---

Monte Rosa Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell---16,761
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell14,515$6.14$89.12K-
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell25,700$13.41$344.64K-
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell35,900$7.78$279.30K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 04, 2024Warmuth Markusdirector, officer President & CEOA-AwardBuy346,000$5.71$1.98M346,000
Jan 04, 2024Wallace Owen B.officer Chief Scientific OfficerA-AwardBuy119,000$5.71$679.49K119,000
Jan 04, 2024Jones Jullian Gofficer Chief Business OfficerA-AwardBuy79,000$5.71$451.09K79,000
Jan 04, 2024Janku Filipofficer Chief Medical OfficerA-AwardBuy121,000$5.71$690.91K121,000
Jan 04, 2024Nickson Philipofficer General CounselA-AwardBuy109,000$5.71$622.39K109,000
Jan 04, 2024Dunn Edmundofficer Principal Accounting OfficerA-AwardBuy35,900$5.71$204.99K35,900
Jan 04, 2024Dunn Edmundofficer Principal Accounting OfficerA-AwardBuy25,000$5.71$142.75K25,000
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell---16,761
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell14,515$6.14$89.12K-
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell25,700$13.41$344.64K-
Aug 18, 2023Dunn Edmundofficer Principal Accounting OfficerSell35,900$7.78$279.30K-
Jul 26, 2023Manning Anthony M.director-A-AwardBuy41,000$6.70$274.70K41,000
Jul 26, 2023Manning Anthony M.director Buy----
Jun 15, 2023Behbahani Alidirector, 10 percent owner A-AwardBuy20,500$6.59$135.09K20,500
Jun 15, 2023Skvarka Jandirector-A-AwardBuy20,500$6.59$135.09K20,500
Jun 15, 2023Siu Christinedirector-A-AwardBuy20,500$6.59$135.09K20,500
Jun 15, 2023SCHIFF ANDREW Ndirector-A-AwardBuy20,500$6.59$135.09K20,500
Jun 15, 2023Mayweg Alexanderdirector-A-AwardBuy20,500$6.59$135.09K20,500
Jun 15, 2023Blackwell Kimberlydirector-A-AwardBuy20,500$6.59$135.09K20,500
Mar 31, 2023Skvarka Jandirector-A-AwardBuy41,000$7.36$301.76K41,000

The last insider sell of Monte Rosa Therapeutics's stock was made by Dunn Edmund on Aug 18 2023, selling - shares at - per share (valued at -).

Monte Rosa Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20247--
Q3 20231425.00%
Q2 20236--
Q1 20239--
Q4 20222--
Q2 20225--
Q1 202282400.00%
Q4 2021-2-
Q2 20217860130.00%
Q1 20213--

7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Monte Rosa Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q3 2023---
Q2 2023---
Q1 2023---
Q4 2022---
Q2 2022---
Q1 2022---
Q4 2021---
Q2 202116--
Q1 2021---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Monte Rosa Therapeutics's stocks.

Monte Rosa Therapeutics Peer Ownership


TickerCompany
GRCLGracell Biotechnologies Inc.
DSGNDesign Therapeutics, Inc.
NKTXNkarta, Inc.
GBIOGeneration Bio Co.
FHTXFoghorn Therapeutics Inc.
KYMRKymera Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
ERASErasca, Inc.
STTKShattuck Labs, Inc.
SANASana Biotechnology, Inc.
IKNAIkena Oncology, Inc.
LYELLyell Immunopharma, Inc.

GLUE Ownership FAQ


Monte Rosa Therapeutics is owned by institutional shareholders (77.62%), insiders (0.71%), and public (21.67%). The largest institutional shareholder of Monte Rosa Therapeutics is NEA MANAGEMENT COMPANY, LLC (14.97% of total shares) and the top mutual fund owner is DSS AMERICAFIRST QUANTITATIVE FUNDS (2.02% of total shares).

Monte Rosa Therapeutics's major institutional shareholders are NEA MANAGEMENT COMPANY, LLC, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, and AVORO CAPITAL ADVISORS LLC. The top five shareholders own together 53.66% of the company's share outstanding.

As of Mar 2024, there are 71 institutional shareholders of Monte Rosa Therapeutics.

NEA MANAGEMENT COMPANY, LLC owns 7.69M shares of Monte Rosa Therapeutics, representing 14.97% of the company's total shares outstanding, valued at $54.23M (as of Mar 2024).

As of Mar 2024, FMR LLC holds 5.34M shares of Monte Rosa Therapeutics (GLUE), compromising 10.39% of the company, valued at $37.65M.

PRICE T ROWE ASSOCIATES INC /MD/ is the third largest holder of Monte Rosa Therapeutics. The company owns 5.1M of the company's shares outstanding (worth $35.93M).